[go: up one dir, main page]

WO2025188180A8 - Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression - Google Patents

Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression

Info

Publication number
WO2025188180A8
WO2025188180A8 PCT/NL2025/050102 NL2025050102W WO2025188180A8 WO 2025188180 A8 WO2025188180 A8 WO 2025188180A8 NL 2025050102 W NL2025050102 W NL 2025050102W WO 2025188180 A8 WO2025188180 A8 WO 2025188180A8
Authority
WO
WIPO (PCT)
Prior art keywords
erbb
cancers
treatment
malignant cells
targeting agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/NL2025/050102
Other languages
French (fr)
Other versions
WO2025188180A1 (en
Inventor
Arie Berdinus BRINKMAN
Jeroen Jilles LAMMERTS VAN BUEREN
Sidney Peter WALKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merus BV
Original Assignee
Merus BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus BV filed Critical Merus BV
Publication of WO2025188180A1 publication Critical patent/WO2025188180A1/en
Publication of WO2025188180A8 publication Critical patent/WO2025188180A8/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the field of ErbB-2 and/or ErbB3 targeting agents, such as antibodies binding ErbB-2 and/or ErbB3. In particular it relates to the field of therapeutic (human) antibodies for the treatment of a ErbB-2/ErbB-3 positive cell, tumor or cancer. More in particular it relates to treating malignant cells, tumors or cancers comprising high NRG1 expression levels.
PCT/NL2025/050102 2024-03-04 2025-03-03 Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression Pending WO2025188180A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2037175 2024-03-04
NL2037175 2024-03-04

Publications (2)

Publication Number Publication Date
WO2025188180A1 WO2025188180A1 (en) 2025-09-12
WO2025188180A8 true WO2025188180A8 (en) 2025-10-02

Family

ID=90717914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2025/050102 Pending WO2025188180A1 (en) 2024-03-04 2025-03-03 Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression

Country Status (2)

Country Link
TW (1) TW202536421A (en)
WO (1) WO2025188180A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2631727T3 (en) * 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Antibodies against ErbB3 and their uses
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
WO2015025866A1 (en) * 2013-08-20 2015-02-26 独立行政法人国立がん研究センター New fusion gene detected in lung cancer
ES3006007T3 (en) 2014-02-28 2025-03-17 Merus Nv Antibody that binds erbb-2 and erbb-3
SG11201908833TA (en) * 2017-03-31 2019-10-30 Merus Nv Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
TW202313987A (en) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 Liquid biopsy assays for detecting nrg1 fusion polynucleotides

Also Published As

Publication number Publication date
TW202536421A (en) 2025-09-16
WO2025188180A1 (en) 2025-09-12

Similar Documents

Publication Publication Date Title
Ortholan et al. Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials
TR200201442T2 (en) Preparation and use of radium-223 for calcified target tissues for pain relief, bone cancer therapy, and keeping bone surface healthy.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MX2024008496A (en) Methods and compositions for treating cancers using antisense.
ZA201907225B (en) Treatment of her2 positive cancers
ZA202304965B (en) Combination therapy for treating cancer
MX2023007436A (en) Therapeutic rna for treating cancer.
MX2025007378A (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2025188180A8 (en) Erbb-2 and erbb3 targeting agents for use in the treatment of malignant cells or cancers that have elevated nrg1 expression
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2023174925A8 (en) Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
MX2025005779A (en) Antibody-drug conjugate, preparation method therefor, and use thereof
MX2025006808A (en) Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
MX2020013883A (en) Oncology treatments using zinc agents.
WO2021127556A8 (en) Methods for treating cancer comprising low dose radiation
MX2021005169A (en) Methods and compositions for treating hepatocellular carcinoma using antisense.
SG148035A1 (en) Gene products differentially expressed in cancerous breast cells and their methods of use
Perera et al. The role of radiotherapy in metastatic bladder cancer
WO2022122765A3 (en) Antibody and taxane combination therapy
Mukaida et al. Clinical evaluation of adjuvant chemoradiotherapy with CDDP, 5-FU, and VP-16 for advanced esophageal cancer
Ravery Brachytherapy versus radical prostatectomy.
TW202604543A (en) P21-engineered monocytes and radiotherapy in solid tumors
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
Santiago et al. Outcomes of combination therapy for stage IIA–IIIB cervical cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25710572

Country of ref document: EP

Kind code of ref document: A1